Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36

Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21

Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget (2015) 1.04

Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp). J Biol Chem (2015) 1.02

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol (2012) 1.00

Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98

Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG. Iran J Pharm Res (2013) 0.94

Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.87

Effects of oral iron chelator deferasirox on human malignant lymphoma cells. Korean J Hematol (2012) 0.85

Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones. ACS Med Chem Lett (2014) 0.83

Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells. Invest New Drugs (2009) 0.79

Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships. PLoS One (2014) 0.78

Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia. J Biol Inorg Chem (2013) 0.77

A selenosemicarbazone complex with copper efficiently down-regulates the 90-kDa heat shock protein HSP90AA1 and its client proteins in cancer cells. BMC Cancer (2014) 0.77

Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes. J Biol Inorg Chem (2016) 0.77

Cytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof. J Biol Inorg Chem (2016) 0.77

G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound. PLoS One (2015) 0.76

Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget (2015) 0.75

In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites. PLoS One (2015) 0.75

Thiosemicarbazone p-Substituted Acetophenone Derivatives Promote the Loss of Mitochondrial Δψ, GSH Depletion, and Death in K562 Cells. Oxid Med Cell Longev (2015) 0.75

Effect of the piperazine unit and metal-binding site position on the solubility and anti-proliferative activity of ruthenium(II)- and osmium(II)- arene complexes of isomeric indolo[3,2-c]quinoline-piperazine hybrids. Inorg Chem (2014) 0.75

Iron Chelators and Exogenic Photosensitizers. Synergy through Oxidative Stress Gene Expression. J Cancer (2017) 0.75

Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J (2003) 5.78

Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 4.19

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36

MicroRNAs inhibit the translation of target mRNAs on the endoplasmic reticulum in Arabidopsis. Cell (2013) 2.28

The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22

Prevention of early flowering by expression of FLOWERING LOCUS C requires methylation of histone H3 K36. Nat Cell Biol (2005) 2.09

Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem (2006) 2.04

Spinal Implants Can Be Inserted in Patients With Deep Spine Infection: Results From a Large Cohort Study. Spine (Phila Pa 1976) (2017) 2.02

Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. J Biol Chem (2009) 2.02

Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02

Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00

Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96

The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86

IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys (2005) 1.84

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67

Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood (2008) 1.63

Cytoskeletal protein 4.1R negatively regulates T-cell activation by inhibiting the phosphorylation of LAT. Blood (2009) 1.57

Biomedical importance of indoles. Molecules (2013) 1.53

The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49

Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol (2008) 1.48

The role of Mediator in small and long noncoding RNA production in Arabidopsis thaliana. EMBO J (2011) 1.48

The stability of mechanical calibration for a kV cone beam computed tomography system integrated with linear accelerator. Med Phys (2006) 1.47

Liver X receptor alpha is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype. Mol Cell Biol (2008) 1.47

Effect of spiritual intelligence, emotional intelligence, psychological ownership and burnout on caring behaviour of nurses: a cross-sectional study. J Clin Nurs (2013) 1.46

N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46

Analysis of BAC-end sequences (BESs) and development of BES-SSR markers for genetic mapping and hybrid purity assessment in pigeonpea (Cajanus spp.). BMC Plant Biol (2011) 1.45

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43

Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood (2004) 1.42

PM2.5 mass and light extinction reconstruction in IMPROVE. J Air Waste Manag Assoc (2003) 1.40

The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40

The Arabidopsis nucleotidyl transferase HESO1 uridylates unmethylated small RNAs to trigger their degradation. Curr Biol (2012) 1.40

Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38

The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38

T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.37

Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31

Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30

Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30

Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem (2005) 1.30

Identification of SR2211: a potent synthetic RORγ-selective modulator. ACS Chem Biol (2012) 1.29

Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29

Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28

A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). Biochim Biophys Acta (2010) 1.28

Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28

Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia (2009) 1.27

Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25

Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24

Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability. Proc Natl Acad Sci U S A (2013) 1.24

What can affect AOD-PM(2.5) association? Environ Health Perspect (2010) 1.23

Acute stimulation of white adipocyte respiration by PKA-induced lipolysis. Diabetes (2010) 1.23

The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22

Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21

Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood (2007) 1.19

Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood (2011) 1.18

Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood (2009) 1.18

Induction of settlement of larvae of the sea urchin Holopneustes purpurascens by histamine from a host alga. Biol Bull (2004) 1.17

Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17

Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16

Kartagener's syndrome: A case series. Lung India (2012) 1.15

Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15

Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORα and RORγ. ACS Chem Biol (2010) 1.14

Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13

The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12

Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11

Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11

Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10

The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09

Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology (2007) 1.09

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08

Synthesis of ZnO nanostructures for low temperature CO and UV sensing. Sensors (Basel) (2012) 1.07

Kinetic and structural evidence for the importance of Tyr236 for the integrity of the Mo active site in a bacterial sulfite dehydrogenase. Biochemistry (2006) 1.06

Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci U S A (2006) 1.06

Intramolecular electron transfer in sulfite-oxidizing enzymes: elucidating the role of a conserved active site arginine. Biochemistry (2009) 1.06

Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05

Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet (2010) 1.05

Expedient construction of the vibsanin E core without the use of protecting groups. Org Lett (2005) 1.05

Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol (2009) 1.05